'Cytokine storms' are a deadly problem in COVID-19. Researchers are testing promising solutions.


Some of the worst cases of COVID-19 involve patients who appear to get better then suddenly deteriorate, their lungs and other organs failing under an overwhelming immune response called a "cytokine storm." Cytokines are proteins sent out by a body's adaptive immune system — B and T cells — to recruit other immune cells to fight an infection. When the immune system doesn't shut off the cytokines, a storm of cells overwhelms organs, exhausting a body's immune response, causing dangerous inflammation, and attacking healthy tissues.
In COVID-19, scavenger cells called macrophages apparently attack and inflame the lungs, allowing liquid to fill air sacs and causing acute respiratory distress syndrome. An otherwise healthy woman in her 20s had a double lung transplant because COVID-19 irreparably destroyed her lungs, a Chicago hospital announced Thursday.
"It has become increasingly clear in the past few months that, at least in a subset of people who have the virus, calming the storm is the key to survival," The New York Times reports. Researchers are starting trials on several drugs to prevent or pacify cytokine storms, and others have reported some success with a dialysis-like device called CytoSorb that filters out cytokines from a patient's blood and returns it to the body.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In China and Italy, doctors had some success with a drug called tocilizumab, marketed as Actemra by Roche, which blocks the cytokine interleukin-6 (IL-6). Another drug, Kineret, blocks a different cytokine, IL-1. A recent study published in the journal Science Immunology reported promising preliminary results from an AstraZeneca cancer drug called Calquence, or acalabrutinib, which aims to stop the cytokines at their root. Using a drug like tocilizumab is "like cutting the branches off a tree," Dr. Louis Staudt, a National Cancer Institute scientist and a lead investigator on the study, tells the Times. "Acalabrutinib is going for the trunk of the tree." AstraZeneca has plans to test the drug in larger trials.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
What to know before turning to AI for financial advice
the explainer It can help you crunch the numbers — but it might also pocket your data
-
Book reviews: 'The Headache: The Science of a Most Confounding Affliction—and a Search for Relief' and 'Tonight in Jungleland: The Making of Born to Run'
Feature The search for a headache cure and revisiting Springsteen's 'Born to Run' album on its 50th anniversary
-
Keith McNally' 6 favorite books that have ambitious characters
Feature The London-born restaurateur recommends works by Leo Tolstoy, John le Carré, and more
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year